Search

Your search keyword '"Kamal Sharma"' showing total 11 results
Start Over Author "Kamal Sharma" Journal journal of the american college of cardiology
11 results on '"Kamal Sharma"'

3. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring

Author

Mukund M. Kumbla, Kamal Sharma, Anil V. Godbole, Shruti Dharmadhikari, Manish Agarwal, Franz H. Messerli, Shyam L. Mathur, Prasita Kshirsagar, Anil Pareek, and Nitin Chandurkar

Subjects
medicine.medical_specialty, hypertension, Ambulatory blood pressure, medicine.drug_class, medicine.medical_treatment, Urology, 030204 cardiovascular system & hematology, low-dose diuretic agent, Essential hypertension, 03 medical and health sciences, 0302 clinical medicine, Hydrochlorothiazide, Internal medicine, medicine, 030212 general & internal medicine, Antihypertensive drug, Thiazide, business.industry, medicine.disease, Blood pressure, Endocrinology, Chlorthalidone, thiazide, Diuretic, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

BackgroundThiazide and thiazide-like diuretic agents are being increasingly used at lower doses. Hydrochlorothiazide (HCTZ) in the 12.5-mg dose remains the most commonly prescribed antihypertensive agent in the United States.ObjectivesThis study compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily, by 24-h ambulatory blood pressure (ABP) monitoring and evaluated efficacy. Because HCTZ has been perceived as a short-acting drug, a third comparison with an extended-release formulation (HCTZ-controlled release [CR]) was added.MethodsThis 12-week comparative, double-blind, outpatient study randomized 54 patients with stage 1 hypertension to receive either chlorthalidone, 6.25 mg, (n = 16); HCTZ 12.5 mg (n = 18); or HCTZ-CR 12.5 mg (n = 20). ABP monitoring was performed at baseline and after 4 and 12 weeks of therapy.ResultsAll 3 treatments significantly (p < 0.01) lowered office BP at weeks 4 and 12 from baseline. At weeks 4 and 12, significant reductions in systolic and diastolic 24-h ambulatory and nighttime BP (p

Published
2016

4. EFFECTS OF SYMPATHETIC BLOCKADE ON RESPONSIVENESS TO VNS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Author

Sanjay Mittal, Rufino Monteiro, Lorenzo A. DiCarlo, Imad Libbus, Jeffrey L. Ardell, Inderjit Anand, Douglas Gregory, Kamal Sharma, and Rajendra K. Premchand

Subjects
medicine.medical_specialty, Ejection fraction, Pharmacological therapy, business.industry, medicine.medical_treatment, Sympathetic blockade, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Heart failure, medicine, Cardiology, In patient, 030212 general & internal medicine, Cardiology and Cardiovascular Medicine, business, Vagus nerve stimulation
Abstract

The effect of beta-blockade (BB) on response to vagus nerve stimulation (VNS) has not been reported in patients with heart failure and reduced ejection fraction (HFrEF). In the ANTHEM-HF Pilot Study, 60 patients received chronic cervical VNS. Background pharmacological therapy remained unchanged

Published
2020

5. LONG-TERM FOLLOW-UP OF REDUCED EJECTION FRACTION HEART FAILURE PATIENTS RECEIVING AUTONOMIC REGULATION THERAPY IN THE ANTHEM-HF PILOT STUDY

Author

Kamal Sharma, Rufino Monteiro, Imad Libbus, Rajendra K. Premchand, Badri Amurthur, Bruce H. KenKnight, Sanjay Mittal, Inderjit Anand, Lorenzo A. DiCarlo, and Jeffrey L. Ardell

Subjects
Cardiac function curve, medicine.medical_specialty, Ejection fraction, business.industry, Long term follow up, medicine.medical_treatment, 030204 cardiovascular system & hematology, medicine.disease, Autonomic regulation, 03 medical and health sciences, 0302 clinical medicine, Heart failure, Internal medicine, medicine, Cardiology, In patient, 030212 general & internal medicine, Cardiology and Cardiovascular Medicine, business, Vagus nerve stimulation
Abstract

Autonomic regulation therapy (ART) via vagus nerve stimulation (VNS) in the ANTHEM-HF Pilot Study has been reported to improve cardiac function and improve symptoms in patients with advanced heart failure (HF) at 6 and 12 months post-titration. Clinical observation of a subset of the randomized

Published
2019

6. COMPARISON OF BACKGROUND PHARMACOLOGIC THERAPY IN THE ANTHEM-HF PILOT STUDY TO CONTEMPORARY TRIALS OF NOVEL HEART FAILURE THERAPIES

Author

Lorenzo A. DiCarlo, Rufino Monteiro, Inderjit Anand, Rajendra K. Premchand, Sanjay Mittal, Kamal Sharma, Badri Amurthur, Imad Libbus, Bruce H. KenKnight, and Jeffrey L. Ardell

Subjects
Autonomic function, medicine.medical_specialty, business.industry, Walk distance, medicine.disease, Autonomic regulation, Heart failure, Internal medicine, Cardiology, Medicine, Pharmacologic therapy, In patient, Cardiology and Cardiovascular Medicine, business, Medical therapy
Abstract

The ANTHEM-HF Pilot Study demonstrated that Autonomic Regulation Therapy (ART) added to Guideline-Directed Medical Therapy (GDMT) improved autonomic function, left ventricular (LV) function, NYHA, 6-minute walk distance (6MWD), and Minnesota Living with Heart Failure score (QoL) in patients with

Published
2019

8. TCTAP A-146 A Novel Abluminal Coated Sirolimus-eluting Stent as a Treatment Option for Diabetic Patients: Results from an All-comers Multicenter Study

Author

Rutvik Trivedi, Kamal Sharma, Sameer Dani, Apurva Vasavada, Nirav Bhalani, Arvind Sharma, Pritesh Parekh, Prathapkumar Natarajapillai, Jayachandran Thejus, Luca Testa, and Chirag C. Sheth

Subjects
medicine.medical_specialty, Multicenter study, business.industry, Sirolimus, medicine.medical_treatment, medicine, Treatment options, Stent, Cardiology and Cardiovascular Medicine, business, Surgery, medicine.drug
Published
2017

9. Fluoroscopy Save Only Protocol Compared With Conventional Fluoroscopy and Cineangiogram in Percutaneous Coronary Intervention

Author

Kamal Sharma, Sharad R. Jain, Gaurav D. Gandhi, and Sanjay Vaghani

Subjects
Protocol (science), medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.medical_treatment, Percutaneous coronary intervention, surgical procedures, operative, Conventional PCI, medicine, Cineangiography, Fluoroscopy, cardiovascular diseases, Radiology, Cardiology and Cardiovascular Medicine, business
Abstract

Conventionally, a combination of both fluoroscopy (FS) and cineangiography (CA) are used during percutaneous coronary intervention (PCI). CA involves higher radiation dosage exposure than regular FS [(1)][1]. However, FS-guided PCI has not been studied in terms of safety and effectiveness in the

Published
2015

11. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.

Author

Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, Agarwal MA, Sharma KH, Mathur SL, and Kumbla MM

Subjects
Adult, Antihypertensive Agents, Diuretics administration & dosage, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypertension physiopathology, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Blood Pressure drug effects, Blood Pressure Monitoring, Ambulatory, Chlorthalidone administration & dosage, Hydrochlorothiazide administration & dosage, Hypertension drug therapy
Abstract

Background: Thiazide and thiazide-like diuretic agents are being increasingly used at lower doses. Hydrochlorothiazide (HCTZ) in the 12.5-mg dose remains the most commonly prescribed antihypertensive agent in the United States., Objectives: This study compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily, by 24-h ambulatory blood pressure (ABP) monitoring and evaluated efficacy. Because HCTZ has been perceived as a short-acting drug, a third comparison with an extended-release formulation (HCTZ-controlled release [CR]) was added., Methods: This 12-week comparative, double-blind, outpatient study randomized 54 patients with stage 1 hypertension to receive either chlorthalidone, 6.25 mg, (n = 16); HCTZ 12.5 mg (n = 18); or HCTZ-CR 12.5 mg (n = 20). ABP monitoring was performed at baseline and after 4 and 12 weeks of therapy., Results: All 3 treatments significantly (p < 0.01) lowered office BP at weeks 4 and 12 from baseline. At weeks 4 and 12, significant reductions in systolic and diastolic 24-h ambulatory and nighttime BP (p < 0.01) were observed with chlorthalidone but not with HCTZ. At weeks 4 (p = 0.015) and 12 (p = 0.020), nighttime systolic ABP was significantly lower in the chlorthalidone group than in the the HCTZ group. With HCTZ therapy, sustained hypertension was converted into masked hypertension. In contrast to the HCTZ group, the HCTZ-CR group also showed a significant (p < 0.01) reduction in 24-h ABP. All 3 treatments were generally safe and well tolerated., Conclusions: Treatment with low-dose chlorthalidone, 6.25 mg daily, significantly reduced mean 24-h ABP as well as daytime and nighttime BP. Due to its short duration of action, no significant 24-h ABP reduction was seen with HCTZ, 12.5 mg daily, which merely converted sustained hypertension into masked hypertension. Thus, low-dose chlorthalidone, 6.25 mg, could be used as monotherapy for treatment of essential hypertension, whereas low-dose HCTZ monotherapy is not an appropriate antihypertensive drug. (Comparative Evaluation of Safety and Efficacy of Hydrochlorothiazide CR with Hydrochlorothiazide and Chlorthalidone in Patients With Stage I Essential Hypertension; CTRI/2013/07/003793)., (Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results